<DOC>
	<DOCNO>NCT00242840</DOCNO>
	<brief_summary>This study ass efficacy subsequent protease inhibitor ( PI ) -containing therapy subject acquire HIV-1 protease mutation whilst receive GW433908 ( fosamprenavir ) -containing regimen .</brief_summary>
	<brief_title>Observational Study Of A Protease Inhibitor ( PI ) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 ( Fosamprenavir )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Fosamprenavir</mesh_term>
	<mesh_term>HIV Protease Inhibitors</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Inclusion criterion : Prior participation study APV30005 AND one follow study : APV30001 , APV30002 , AZL30006 , APV30003 . Must fail virologically ( &gt; 1000 copy two consecutive timepoints ) screen genotype evidence least one new APVassociated protease mutation : V32I ( +/ I47V ) , I50V , I54L/M , I84V acquire since commence treatment GW433908 . Exclusion criterion : Have 2 primary resistance mutation D30N , G48V , V82A/F/T/S L90M . Have medical need use nonnucleoside reductase transferase inhibitor ( NNRTI ) . Have acute CDC Class C event require therapeutic intervention . Are pregnant lactating . Have condition opinion investigator would preclude participation .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>protease inhibitor</keyword>
	<keyword>ritonavir</keyword>
	<keyword>GW433908</keyword>
	<keyword>HIV-1</keyword>
	<keyword>fosamprenavir</keyword>
</DOC>